NEW YORK, Oct. 18, 2017 /PRNewswire/ -- EW Healthcare Partners ("EW"), a leading healthcare growth equity firm with a global investment practice, has announced the addition of three senior executives to their investment team:
- Lamberto Andreotti, former Chairman and CEO of Bristol Myers Squibb, a global pharmaceutical company, has joined as Senior Advisor in the New York office;
- William A. "Bill" Hawkins, III, former Chairman and CEO of Medtronic, a global medical device company, has joined as Senior Advisor in the New York office; and
- Bryan Morton, Founder, President and CEO of EUSA Pharma "I", a former EW portfolio company that was sold to Jazz Pharmaceuticals for $700 million, and Executive Chairman of EUSA Pharma "II", has joined as Operating Partner in the London office.
Scott Barry, Managing Director who heads the EW New York office, commented: "We are delighted and honored to have three such accomplished senior healthcare executives join our investment team. Their in-depth operational experience, worldwide network of contacts, and ability to identify and take advantage of the fastest growing segments in pharmaceutical and medical device industries will be most valuable to the firm and our portfolio companies."
Bill Hawkins said: "I am pleased to join the EW team which is characterized by an extensive operating experience across the entire healthcare industry. I look forward to helping the firm identify and invest in some of the fastest growing healthcare companies and helping the investment team accelerate the growth of these businesses."
Lamberto Andreotti is Appointed Senior Advisor in the New York Office
Lamberto Andreotti is a former Chairman and CEO of Bristol Myers Squibb ("BMS"), a global pharmaceutical company with $100 billion market capitalization. Lamberto first joined BMS in 1998 as Vice President and General Manager of European Oncology and Italy, and advanced to President, Europe in 2000, President, International in 2002 and President, Pharmaceuticals in 2005. He became Chief Operating Officer in 2008 and was elected to the Board of Directors the following year. He was appointed CEO in 2010 and ultimately appointed Chairman of the Board in 2015. During Lamberto's tenure at BMS, he was credited with leading the company in enhancing the value of the company's pipeline, generating blockbuster sales, negotiating valuable partnerships with other major pharmaceutical companies, and achieving excellent shareholder returns. Among many other accomplishments under Lamberto's leadership, BMS led the development of a new class of drugs in immuno-oncology, which has revolutionized the treatment of many cancers.
Before joining BMS, Lamberto held the positions of Senior Corporate Vice President and President of Oncology at Pharmacia & Upjohn, and served in various senior roles at Recordati, Farmitalia Carlo Erba and KABI Pharmacia previously.
Lamberto also is a member of the Board of Directors of DowDuPont Inc. following the merger of DuPont and The Dow Chemical Company. He also serves as a Director for the American Italian Cancer Foundation.
Originally from Rome, Italy, Lamberto received his Bachelor's degree in Engineering from Università La Sapienza of Rome and his Master of Science degree from the Massachusetts Institute of Technology.
William A. "Bill" Hawkins, III is Appointed Senior Advisor in the New York Office
Bill Hawkins is a former Chairman and CEO of Medtronic, a global medical device company with $100 billion market capitalization. He brings to EW many years of experience in building some of the most dynamic and innovative medical device companies, and is among the most respected business leaders in the healthcare industry. Prior to Medtronic, Bill served as President and Chief Executive Officer of medical device company Novoste Corporation, where he led the development of the company's innovative stents. Previously, Bill held senior leadership positions at American Home Products, Johnson & Johnson, Guidant Corporation and Eli Lilly & Company.
Bill is well-known to EW as Chairman of the Board of Directors of Bioventus, a Fund VIII growth equity portfolio company, where he serves on the Board together with EW Co-Founder, Marty Sutter and EW Operating Partner, Guido Neels. During his tenure as Chairman, Bill has guided the evolution of Bioventus into a rapidly growing and most profitable orthobiologics company with annual revenue approaching $300 million.
Bill received his Bachelor's degree in Electrical and Biomedical Engineering from Duke University in 1976, and an MBA from the Darden School of Business, University of Virginia, in 1982. Bill is an AIMBE Fellow and was elected to the National Academy of Engineering in 2016.
Bryan Morton, CBE is Appointed Operating Partner in the London Office
Bryan Morton was the Founder, President and Chief Executive Officer of EUSA Pharma "I", a transatlantic specialty pharmaceutical company focused on oncology and critical care, and a prior EW portfolio company. After five years of rapid growth, EUSA was sold to Jazz Pharmaceuticals for $700 million in 2012. Three years later, Bryan reacquired, together with EW, certain EUSA assets from Jazz Pharmaceuticals to create a new rapidly growing oncology specialty pharma company, EUSA Pharma "II" where Bryan is now the Executive Chairman. Previously, Bryan was the CEO of Zeneus Pharma, which he founded by purchasing Elan's European business for $120 million. Zeneus was subsequently acquired by Cephalon for $360 million after two years of rapid growth.
Bryan's entrepreneurial success is built on 30 years of commercial business development and general management experience in the pharmaceutical industry, spent largely with Merck & Co Inc. and BMS. He has extensive international experience, particularly in the US and Europe, having held senior positions, including at the Board and SVP level, in America, the UK, Belgium and Australia.
Bryan holds an MBA from Durham University and is an Honorary Professor at Durham University Business School. Bryan also holds a Bachelor of Science degree in Pharmacology from Aberdeen University in Scotland and is a graduate of the INSEAD European Management Program. In 2016, Bryan was honored by Her Majesty the Queen, and was awarded a CBE (Commander of the Most Excellent Order of the British Empire) for his services to the Healthcare Industry.
About EW Healthcare Partners
With over $3.0 billion under management, EW Healthcare Partners is one of the largest and oldest growth equity firms pursuing investments in pharmaceuticals, medical devices, healthcare services, and healthcare information technology. Since its founding in 1985, EW Healthcare Partners has maintained its singular commitment to the healthcare industry and has been involved in the founding, investing, and/or management of over 150 healthcare companies, ranging across sectors, stages, and geographies. The team is comprised of over 20 senior investment professionals with offices in Palo Alto, Houston, New York, and London.
For more information, please see www.ewhealthcare.com
Managing Director, New York
SOURCE EW Healthcare Partners